Completed PHASE1 INTERVENTIONAL 5-arm NCT06559527

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0487-0111 in Participants With Various Degrees of Renal Impairment and Normal Renal Function

Sponsor: Novo Nordisk A/S

Conditions Diabetes Mellitus, Type 2 Obesity Overweight

Interventions NNC0487-0111

Updated 3 times since 2024 Last updated: Mar 28, 2025 Started: Aug 20, 2024 Primary completion: Feb 24, 2025 Completion: Mar 5, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diabetes Mellitus, Type 2 and Obesity and is currently completed. Novo Nordisk A/S leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Aug 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany